PKC

PKC

Protein kinase C (PKC) denotes a family of serine/threonine kinases that mediate signal transduction downstream of receptors and second messengers. PKC isoforms transduce signals from molecules such as diacylglycerol and calcium to regulate processes implicated in cell growth, differentiation, apoptosis, and synaptic plasticity. Major research on PKC has involved investigators and institutions across biomedical centers, translational consortia, and pharmaceutical companies.

Overview

PKC was first characterized in studies involving Louis Slotta-era biochemical efforts and later biochemical purification methods associated with groups at Rockefeller University, Harvard Medical School, and Max Planck Society laboratories that investigated protein phosphorylation. Work by laboratories allied with The Rockefeller University and Stanford University clarified roles for PKC in receptor-coupled signaling cascades tied to ligands studied by researchers at Merck & Co. and Pfizer. Structural biology contributions from teams at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory informed models later used by investigators at Massachusetts Institute of Technology and University of California, San Francisco. PKC research has engaged diverse funders including National Institutes of Health, Wellcome Trust, and European Research Council.

Structure and Isoforms

PKC family members are categorized into classical, novel, and atypical subfamilies based on domain architecture and cofactor requirements, with contributions to primary sequence annotation from consortia at Ensembl, UniProt, and GenBank. Classical isoforms contain regulatory C1 and C2 domains and a catalytic domain homologous to kinases described in studies at Cold Spring Harbor Laboratory; notable classical isoforms include PRKCA, PRKCB, and PRKCG, which were sequenced in programs at Sanger Institute and Johns Hopkins University. Novel isoforms (e.g., PRKCD, PRKCE) lack calcium-sensitive C2 sequences, a distinction mapped in comparative genomics projects at Broad Institute and European Nucleotide Archive. Atypical isoforms (e.g., PRKCI, PRKCZ) possess divergent regulatory modules characterized in structural efforts at Laboratory of Molecular Biology and Max Planck Institute for Biochemistry. Domain boundaries and phosphorylation sites were validated by mass spectrometry teams at Stanford University School of Medicine and The Scripps Research Institute and integrated into resources maintained by Protein Data Bank and Pfam.

Activation and Regulation

Activation of PKC isoforms is regulated by second messengers produced by receptor systems studied at University of Cambridge and Yale University, including diacylglycerol generated by phospholipase C pathways researched in laboratories at Columbia University and University of Chicago. Classical PKCs respond to both diacylglycerol and calcium influxes characterized in electrophysiology work from University College London and University of Oxford. Novel PKCs respond to diacylglycerol but are calcium-independent, as shown in cell signaling studies at Imperial College London and University of Pennsylvania. Atypical PKCs are regulated by protein–protein interactions and phosphorylation mediated by kinases evaluated by MIT-affiliated groups and University of California, Berkeley researchers. Upstream modulators include receptors and adaptors described in investigations at National Cancer Institute, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center; downstream scaffolds include RACK proteins and MAGUK family members characterized at Cold Spring Harbor Laboratory and Max Delbrück Center. Post-translational control mechanisms such as phosphorylation, ubiquitination, and proteolysis were elucidated by proteomics collaborations involving EMBL-EBI and ProteomeXchange partners.

Cellular Functions and Signaling Pathways

PKC isoforms function in pathways governing proliferation, migration, synaptic transmission, and immune responses, connecting to receptors and pathways originally delineated in landmark studies at Johns Hopkins University, Karolinska Institute, and Institut Pasteur. In neuronal systems, PKC modulates plasticity alongside proteins researched at Cold Spring Harbor Laboratory and Max Planck Institute for Neurobiology; in cardiovascular biology PKC roles intersect with pathways studied at Cleveland Clinic and Mount Sinai Health System. PKC participates in mitogen-activated cascades involving MAPKs and PI3K/Akt axes characterized at ETH Zurich and Yale University School of Medicine. In immune cells, PKC isoforms intersect with antigen receptor signaling explored at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center. PKC substrates include cytoskeletal regulators, transcription factors such as NF-κB and CREB analyzed in laboratories at University of Toronto and University of Michigan, and metabolic regulators examined at University of California, San Diego and University of Texas Southwestern Medical Center.

Role in Disease and Therapeutics

Aberrant PKC signaling is implicated in cancer, neurodegeneration, cardiac hypertrophy, diabetes, and immune disorders; clinical and translational studies have been conducted at MD Anderson Cancer Center, Mayo Clinic, Baylor College of Medicine, and Johns Hopkins Hospital. Oncogenic and tumor-suppressive roles for specific isoforms were reported in multi-center studies involving European Organisation for Research and Treatment of Cancer and National Cancer Institute cooperative groups. Neurodegenerative connections were pursued by teams at University College London Hospital and Karolinska University Hospital. Therapeutic modulation of PKC has been targeted by small molecules and biologics developed in pipelines at Novartis, GlaxoSmithKline, AstraZeneca, and biotech firms incubated at Cambridge Biomedical Campus and Biopolis. Drug discovery efforts leveraged high-throughput screening platforms at Genentech and structural screening at Diamond Light Source. Clinical trials of PKC modulators have been registered with networks coordinated by ClinicalTrials.gov and evaluated in consortia including European Medicines Agency oversight. Biomarker strategies and companion diagnostics were developed in partnerships among Foundation Medicine, academic centers such as University of Pennsylvania Perelman School of Medicine, and precision oncology programs at Memorial Sloan Kettering Cancer Center.

Category:Protein kinases